| Field | Specification |
|---|---|
| Target | |
| Alternative names | Vascular endothelial growth factor receptor 3; VEGFR-3; Fms-like tyrosine kinase 4; FLT-4; Tyrosine-protein kinase receptor FLT4; FLT4; VEGFR3 |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | E. coli-derived human VEGF Receptor 3 recombinant protein (Position: Y25-N259). |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody detects vascular endothelial growth factor receptor 3 (gene FLT4) in human, mouse and rat samples and is validated for ELISA, flow cytometry, ICC/IF, IHC and Western blot. The predicted molecular weight is 152.8 kDa, and the supplier reports an observed band at about 153 kDa.
Vascular endothelial growth factor receptor 3 (VEGFR-3, FLT4) is a receptor tyrosine kinase activated by VEGF-C and VEGF-D. It is essential for the growth of lymphatic vessels and also contributes to early blood vessel development. VEGFR-3 is a common lymphatic endothelial marker, and FLT4 mutations cause hereditary lymphedema (Milroy disease).
| Target | Vascular endothelial growth factor receptor 3 (gene FLT4; UniProt P35916, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human, Mouse, Rat |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4 |
| Calculated MW | 152.8 kDa |
| Observed MW | 153 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.1–0.5 µg/mL |
|---|---|
| IHC (paraffin sections) | 0.5–1 µg/mL |
| IHC (frozen sections) | 0.5–1 µg/mL |
| Immunocytochemistry / Immunofluorescence | 2 µg/mL |
| Flow cytometry (fixed cells) | 1–3 µg/1×106 cells |
| ELISA | 0.1–0.5 µg/mL |
Samples with a confirmed band (WB): rat liver tissue.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 50 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:10000, ECL detection.
Samples with confirmed staining (IHC): human lung cancer tissue, human placenta tissue, human prostatic cancer tissue, rat liver tissue, human rectal cancer tissue, mouse liver tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in citrate buffer (pH 6).
Samples with confirmed staining (IHC): human placenta tissue.
Samples with confirmed staining (ICC/IF): A431 cells.
Samples with a confirmed signal (flow cytometry): U2OS cells.
Immunogen
Recombinant human VEGF Receptor 3 fragment (Tyr25–Asn259), expressed in E. coli.
Reactivity Notes
The supplier lists reactivity with human, mouse and rat. UniProt places vascular endothelial growth factor receptor 3 in the cell membrane, cytoplasm and nucleus. Tissue expression noted by UniProt (human): Detected in endothelial cells (at protein level). The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
Min Chen et al. (2025) Platelet activation relieves liver portal hypertension via the lymphatic system though the classical vascular endothelial growth factor receptor 3 signaling pathway. World Journal of Gastroenterology. 10.3748/wjg.v31.i10.100194
Chao Li et al. (2013) Expression of Angiopoietin-2 and Vascular Endothelial Growth Factor Receptor-3 Correlates with Lymphangiogenesis and Angiogenesis and Affects Survival of Oral Squamous Cell Carcinoma. PLoS One. 10.1371/journal.pone.0075388
Mi Zhou et al. (2010) Lymphatic vessel density as a predictor of lymph node metastasis and its relationship with prognosis in urothelial carcinoma of the bladder. BJU International. 10.1111/j.1464-410X.2010.09725.x
Xiuming Li et al. (2021) Expression levels of VEGF‑C and VEGFR‑3 in renal cell carcinoma and their association with lymph node metastasis. Experimental and Therapeutic Medicine. 10.3892/etm.2021.9986
Ren Shun-xiang et al. (2009) Antitumor activity of endogenous mFlt4 displayed on a T4 phage nanoparticle surface. ACTA Pharmacologica Sinica. 10.1038/aps.2009.44
Ming-Xu Da et al. (2007) Expression of Cyclooxygenase-2 and Vascular Endothelial Growth Factor-C Correlates with Lymphangiogenesis and Lymphatic Invasion in Human Gastric Cancer. Archives of Medical Research. 10.1016/j.arcmed.2007.06.021
Yang Sheng et al. (2010) Interleukin-18 suppresses angiogenesis and lymphangiogenesis in implanted Lewis lung cancer. Chinese Journal of Cancer Research. 10.1007/s11670-010-0303-5
